Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
CD8-Positive T-Lymphocytes
/ immunology
Epitopes, T-Lymphocyte
/ administration & dosage
Female
Humans
Immunologic Memory
Influenza A Virus, H7N9 Subtype
/ genetics
Influenza Vaccines
/ administration & dosage
Lung
/ immunology
Mice
Mice, Inbred BALB C
Orthomyxoviridae Infections
/ immunology
Respiratory Syncytial Virus, Human
/ immunology
Vaccines, Attenuated
/ administration & dosage
Live attenuated influenza vaccine
Respiratory syncytial virus
T cell immunity
Tissue-resident memory T cells
Viral vector
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
28
02
2020
revised:
30
05
2020
accepted:
16
06
2020
pubmed:
26
6
2020
medline:
13
7
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) can cause recurrent infection in people because it does not stimulate a long-lived immunological memory. There is an urgent need to develop a safe and efficacious vaccine against RSV that would induce immunological memory without causing immunopathology following natural RSV infection. We have previously generated two recombinant live attenuated influenza vaccine (LAIV) viruses that encode immunodominant T-cell epitopes of RSV M2 protein in the neuraminidase or NS1 genes. These chimeric vaccines afforded protection against influenza and RSV infection in mice, without causing pulmonary eosinophilia or inflammatory RSV disease. The current study assessed the formation of influenza-specific and RSV-specific CD4 and CD8 T-cell responses in the lungs of mice, with special attention to the lung tissue-resident memory T cell subsets (T
Identifiants
pubmed: 32585323
pii: S0166-3542(20)30278-3
doi: 10.1016/j.antiviral.2020.104864
pmc: PMC7313889
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes, T-Lymphocyte
0
Influenza Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104864Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
J Immunol. 2018 Jul 1;201(1):134-144
pubmed: 29760191
Expert Rev Vaccines. 2020 Jan;19(1):43-55
pubmed: 31903816
Curr Top Microbiol Immunol. 2013;372:3-38
pubmed: 24362682
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Immunity. 2014 Dec 18;41(6):886-97
pubmed: 25526304
J Exp Med. 1997 Aug 4;186(3):421-32
pubmed: 9236194
Nat Immunol. 2013 Dec;14(12):1294-301
pubmed: 24162776
Mucosal Immunol. 2017 Mar;10(2):545-554
pubmed: 27220815
J Med Virol. 2020 Feb;92(2):129-138
pubmed: 31502669
J Virol. 2001 Oct;75(19):8899-908
pubmed: 11533153
Viral Immunol. 2017 Jul/Aug;30(6):438-450
pubmed: 28418771
Cell Mol Life Sci. 2015 Jul;72(13):2461-73
pubmed: 25577280
Expert Rev Vaccines. 2018 Nov;17(11):977-987
pubmed: 30365908
Immunity. 2013 Oct 17;39(4):687-96
pubmed: 24076049
J Immunol. 2007 Oct 15;179(8):5415-24
pubmed: 17911628
Crit Rev Immunol. 2018;38(2):79-103
pubmed: 29953389
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14999-5004
pubmed: 18818306
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14
pubmed: 10725408
Nature. 1994 Nov 10;372(6502):190-3
pubmed: 7969453
Pathogens. 2019 Sep 11;8(3):
pubmed: 31514485
J Immunol. 2007 Apr 1;178(7):4506-16
pubmed: 17372009
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
Vet Pathol. 2012 Jan;49(1):32-43
pubmed: 22135019
Front Immunol. 2018 Mar 26;9:515
pubmed: 29632527
J Virol. 2014 Mar;88(6):3135-43
pubmed: 24371055
J Infect Dis. 1991 Apr;163(4):693-8
pubmed: 2010624
Virol J. 2011 Jul 29;8:375
pubmed: 21801372
J Immunol. 2010 Oct 15;185(8):4673-80
pubmed: 20833834
Vaccine. 2017 Jan 11;35(3):489-495
pubmed: 27889256
Bull Exp Biol Med. 2016 Aug;161(4):533-7
pubmed: 27590768
Front Immunol. 2018 Mar 02;9:323
pubmed: 29552008
Vaccine. 2010 Nov 23;28(50):8015-25
pubmed: 20934458
J Immunol. 2000 Jun 15;164(12):6583-92
pubmed: 10843718
Bull Exp Biol Med. 2019 Mar;166(5):631-636
pubmed: 30903496
Nat Protoc. 2014 Jan;9(1):209-22
pubmed: 24385150
Expert Rev Vaccines. 2016 Oct;15(10):1241-3
pubmed: 27385419
Mucosal Immunol. 2015 Sep;8(5):1060-71
pubmed: 25586557
J Clin Invest. 2020 Jan 2;130(1):523-538
pubmed: 31815739
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Antiviral Res. 2019 Aug;168:9-17
pubmed: 31075351
Am J Pathol. 2011 Jan;178(1):150-60
pubmed: 21224053
J Infect Dis. 2017 May 15;215(10):1527-1535
pubmed: 28368530
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27468427
PLoS Pathog. 2018 Jan 2;14(1):e1006810
pubmed: 29293660
J Clin Invest. 1991 Sep;88(3):1026-33
pubmed: 1909350
PLoS Pathog. 2015 Mar 13;11(3):e1004757
pubmed: 25769044
Hum Vaccin Immunother. 2018;14(12):2964-2970
pubmed: 30024831
J Immunol. 2015 Jul 1;195(1):203-9
pubmed: 26026054
J Immunol. 1993 Aug 15;151(4):2032-40
pubmed: 8345194